Improved Immunogenicity of a Vaccination Regimen Combining a DNA Vaccine Encoding Brucella melitensis Outer Membrane Protein 31 (Omp31) and Recombinant Omp31 Boosting
Open Access
- 1 July 2007
- journal article
- research article
- Published by American Society for Microbiology in Clinical and Vaccine Immunology
- Vol. 14 (7) , 869-874
Abstract
In the present study, we report an attempt to improve the immunogenicity of the Omp31 antigen by a DNA prime-protein boost immunization regimen. We immunized BALB/c mice with an Omp31 DNA vaccine (pCIOmp31) followed by boosting with recombinant Omp31 (rOmp31) in incomplete Freund's adjuvant and characterized the resulting immune responses and the protective efficacy against Brucella ovis and B. melitensis infection. Immunoglobulin G1 (IgG1) and IgG2a titers were higher in sera from pCIOmp31/rOmp31-immunized mice than in sera from mice immunized with pCIOmp31 or rOmp31 alone. Splenocytes from pCIOmp31/rOmp31-immunized mice produced significantly higher levels of gamma interferon than did those from mice given rOmp31 alone. In contrast, interleukin 2 (IL-2) production levels were comparable between the two groups of immunized mice. Cells from all immunized mice produced undetectable levels of IL-4. Notably, rOmp31 stimulated IL-10 production in the pCIOmp31/rOmp31-immunized group but not in the pCIOmp31- or rOmp31-immunized group. Although the prime-boost regimen induced specific cytotoxic responses, these responses could not reach the levels achieved by the pCIOmp31 immunization. In conclusion, pCIOmp31 priming followed by rOmp31 boosting led to moderately improved protection against a challenge with B. ovis or B. melitensis .Keywords
This publication has 34 references indexed in Scilit:
- Selection of Protective Epitopes for Brucella melitensis by DNA VaccinationInfection and Immunity, 2005
- A DNA Vaccine Coding for theBrucellaOuter Membrane Protein 31 Confers Protection againstB. melitensisandB. ovisInfection by Eliciting a Specific Cytotoxic ResponseInfection and Immunity, 2005
- Different Responses of Macrophages to Smooth and RoughBrucellaspp.: Relationship to VirulenceInfection and Immunity, 2004
- Antibody Reactivity to Omp31 fromBrucella melitensisin Human and Animal Infections by Smooth and Rough BrucellaeClinical and Vaccine Immunology, 2004
- Molecular Host-Pathogen Interaction in Brucellosis: Current Understanding and Future Approaches to Vaccine Development for Mice and HumansClinical Microbiology Reviews, 2003
- Interferon‐γ is crucial for surviving a Brucella abortus infection in both resistant C57BL/6 and susceptible BALB/c miceImmunology, 2001
- Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunityImmunological Reviews, 1999
- Immunization of mice with recombinant L7L12 ribosomal protein confers protection against Brucella abortus infectionVaccine, 1996
- An Overview of Human BrucellosisClinical Infectious Diseases, 1995
- Brucella melitensis Rev-1 vaccine as a cause of human brucellosisThe Lancet, 1993